Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia
| Autor: | Berend J. Slotman, Mary Ann Clark, Enis Özyar, Myungsoo Kim, Jun Itami, Agnès Tallet, Jürgen Debus, Raphael Pfeffer, PierCarlo Gentile, Yukihiro Hama, Nicolaus Andratschke, Olivier Riou, Philip Camilleri, Claus Belka, Magali Quivrin, BoKyong Kim, Anders Pedersen, Mette van Overeem Felter, Young Il Kim, Jin Ho Kim, Martin Fuss, Vincenzo Valentini |
|---|---|
| Přispěvatelé: | Ulsan National Institute of Science and Technology (UNIST), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Heidelberg, Medical Faculty, University hospital of Zurich [Zurich], Hôpital de Sia [Wallis], Ludwig-Maximilians-Universität München (LMU), German Cancer Consortium [Heidelberg] (DKTK), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Service de radiothérapie [Centre Georges-François Leclerc], UNICANCER-UNICANCER, Danmarks Tekniske Universitet = Technical University of Denmark (DTU), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Acibadem University Dspace |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Male
SBRT MR-IGRT Stereotactic body radiotherapy Radiotherapy Planning Computer-Assisted [SDV]Life Sciences [q-bio] Stereotactic ablative radiation therapy Radiotherapy Dosage Radiosurgery Magnetic Resonance Imaging On-table adaptive radiation therapy Oncology Care patterns MRI-guided radiotherapy Humans oART Radiology Nuclear Medicine and imaging Radiotherapy Intensity-Modulated Particle Accelerators ART Radiotherapy Image-Guided SABR |
| Zdroj: | RADIATION ONCOLOGY RADIATION ONCOLOGY, 2022, 17 (1), ⟨10.1186/s13014-022-02114-2⟩ |
| DOI: | 10.1186/s13014-022-02114-2⟩ |
| Popis: | Background Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Our objective was to describe patterns of 0.35 Tesla (T)-MRgRT utilization in Europe and Asia among early adopters of this novel technology. Methods Anonymized administrative data from all 0.35T-MRgRT treatment systems in Europe and Asia were extracted for patients who completed treatment from 2015 to 2020. Detailed treatment information was analyzed for all MR-linear accelerators (linac) and -cobalt systems. Results From 2015 through the end of 2020, there were 5796 completed treatment courses delivered in 46,389 individual fractions. 23.5% of fractions were adapted. Ultra-hypofractionated (UHfx) dose schedules (1–5 fractions) were delivered for 63.5% of courses, with 57.8% of UHfx fractions adapted on-table. The most commonly treated tumor types were prostate (23.5%), liver (14.5%), lung (12.3%), pancreas (11.2%), and breast (8.0%), with increasing compound annual growth rates (CAGRs) in numbers of courses from 2015 through 2020 (pancreas: 157.1%; prostate: 120.9%; lung: 136.0%; liver: 134.2%). Conclusions This is the first comprehensive study reporting patterns of utilization among early adopters of a 0.35T-MRgRT system in Europe and Asia. Intrafraction MR image-guidance, advanced motion management, and increasing adoption of on-table adaptive RT have accelerated a transition to UHfx regimens. MRgRT has been predominantly used to treat tumors in the upper abdomen, pelvis and lungs, and increasingly with adaptive replanning, which is a radical departure from legacy radiotherapy practices. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|